Multicenter retrospective study of chemotherapy in advanced pancreatic adenosquamous carcinoma
Prof. Aziz Zaanan
Pancreatic adenosquamous carcinoma (PASC) accounts for up to 5 % of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. A multicenter retrospective study in France found that among patients with advanced pancreatic adenosquamous carcinoma, first-line FOLFIRINOX or the combination of gemcitabine and nab-paclitaxel resulted in better progression-free and overall survival compared to other chemotherapy regimens.
